Tags

Type your tag names separated by a space and hit enter

[Polycystic ovary syndrome. New pathophysiological discoveries--therapeutic consequences].
Ugeskr Laeger. 2005 Aug 22; 167(34):3147-51.UL

Abstract

Polycystic ovary syndrome (PCOS) is characterised by anovulation, infertility and hyperandrogenism. The condition affects about 5-10% of women in the reproductive age group. Insulin resistance has proven to be a key factor in the pathogenesis of PCOS. There are several similarities between PCOS and the metabolic syndrome, and PCOS may be a risk factor for development of type 2 diabetes and cardiovascular disease. The treatment of PCOS has, so far, been focussed on treatment of the clinical signs and symptoms. Oral contraceptives have been the standard treatment. There is now a greater focus on the management of the metabolic consequences of PCOS, primarily through lifestyle intervention to achieve weight loss and increase physical activity. Metformin has proven to be effective in the management of the metabolic disturbances, anovulation and hirsutism and is now a widely accepted therapy. The thiazolidinediones (pio- and rosiglitazone), a novel class of insulin-sensitising agents, also seem to ameliorate the metabolic disturbances and clinical symptoms characterizing PCOS, but more randomised, controlled trials are needed before clinical guidelines can be determined.

Authors+Show Affiliations

H:S Hvidovre Hospital, Gynaekologisk-obstetrisk Afdeling og Endokrinologisk Klinik, Hvidovre. pernillefsvendsen@hotmail.comNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article
Review

Language

dan

PubMed ID

16117910

Citation

Svendsen, Pernille Fog, et al. "[Polycystic Ovary Syndrome. New Pathophysiological Discoveries--therapeutic Consequences]." Ugeskrift for Laeger, vol. 167, no. 34, 2005, pp. 3147-51.
Svendsen PF, Nilas L, Nørgaard K, et al. [Polycystic ovary syndrome. New pathophysiological discoveries--therapeutic consequences]. Ugeskr Laeger. 2005;167(34):3147-51.
Svendsen, P. F., Nilas, L., Nørgaard, K., & Madsbad, S. (2005). [Polycystic ovary syndrome. New pathophysiological discoveries--therapeutic consequences]. Ugeskrift for Laeger, 167(34), 3147-51.
Svendsen PF, et al. [Polycystic Ovary Syndrome. New Pathophysiological Discoveries--therapeutic Consequences]. Ugeskr Laeger. 2005 Aug 22;167(34):3147-51. PubMed PMID: 16117910.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Polycystic ovary syndrome. New pathophysiological discoveries--therapeutic consequences]. AU - Svendsen,Pernille Fog, AU - Nilas,Lisbeth, AU - Nørgaard,Kirsten, AU - Madsbad,Sten, PY - 2005/8/25/pubmed PY - 2005/8/27/medline PY - 2005/8/25/entrez SP - 3147 EP - 51 JF - Ugeskrift for laeger JO - Ugeskr Laeger VL - 167 IS - 34 N2 - Polycystic ovary syndrome (PCOS) is characterised by anovulation, infertility and hyperandrogenism. The condition affects about 5-10% of women in the reproductive age group. Insulin resistance has proven to be a key factor in the pathogenesis of PCOS. There are several similarities between PCOS and the metabolic syndrome, and PCOS may be a risk factor for development of type 2 diabetes and cardiovascular disease. The treatment of PCOS has, so far, been focussed on treatment of the clinical signs and symptoms. Oral contraceptives have been the standard treatment. There is now a greater focus on the management of the metabolic consequences of PCOS, primarily through lifestyle intervention to achieve weight loss and increase physical activity. Metformin has proven to be effective in the management of the metabolic disturbances, anovulation and hirsutism and is now a widely accepted therapy. The thiazolidinediones (pio- and rosiglitazone), a novel class of insulin-sensitising agents, also seem to ameliorate the metabolic disturbances and clinical symptoms characterizing PCOS, but more randomised, controlled trials are needed before clinical guidelines can be determined. SN - 1603-6824 UR - https://www.unboundmedicine.com/medline/citation/16117910/[Polycystic_ovary_syndrome__New_pathophysiological_discoveries__therapeutic_consequences]_ DB - PRIME DP - Unbound Medicine ER -